Skip to main content
main-content

01.08.2011 | Research article | Ausgabe 4/2011 Open Access

Breast Cancer Research 4/2011

Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study

Zeitschrift:
Breast Cancer Research > Ausgabe 4/2011
Autoren:
Alina Vrieling, Rebecca Hein, Sascha Abbas, Andreas Schneeweiss, Dieter Flesch-Janys, Jenny Chang-Claude
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

AV participated in the follow up field work, carried out the data analysis and drafted the manuscript. RH contributed to the data analysis. SA carried out the 25(OH)D measurements. AS supported the follow up field work and contributed to clinical aspects and data interpretation. DFJ participated in the design of the study and coordination in the Hamburg study region. JCC conceived the study, participated in its design and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.

Abstract

Introduction

Vitamin D has been postulated to be involved in cancer prognosis. Thus far, only two studies reported on its association with recurrence and survival after breast cancer diagnosis yielding inconsistent results. Therefore, the aim of our study was to assess the effect of post-diagnostic serum 25-hydroxyvitamin D [25(OH)D] concentrations on overall survival and distant disease-free survival.

Methods

We conducted a prospective cohort study in Germany including 1,295 incident postmenopausal breast cancer patients aged 50-74 years. Patients were diagnosed between 2002 and 2005 and median follow-up was 5.8 years. Cox proportional hazards models were stratified by age at diagnosis and season of blood collection and adjusted for other prognostic factors. Fractional polynomials were used to assess the true dose-response relation for 25(OH)D.

Results

Lower concentrations of 25(OH)D were linearly associated with higher risk of death (hazard ratio (HR) = 1.08 per 10 nmol/L decrement; 95% confidence interval (CI), 1.00 to 1.17) and significantly higher risk of distant recurrence (HR = 1.14 per 10 nmol/L decrement; 95%CI, 1.05 to 1.24). Compared with the highest tertile (≥ 55 nmol/L), patients within the lowest tertile (< 35 nmol/L) of 25(OH)D had a HR for overall survival of 1.55 (95%CI, 1.00 to 2.39) and a HR for distant disease-free survival of 2.09 (95%CI, 1.29 to 3.41). In addition, the association with overall survival was found to be statistically significant only for 25(OH)D levels of blood samples collected before start of chemotherapy but not for those of samples taken after start of chemotherapy (P for interaction = 0.06).

Conclusions

In conclusion, lower serum 25(OH)D concentrations may be associated with poorer overall survival and distant disease-free survival in postmenopausal breast cancer patients.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2011

Breast Cancer Research 4/2011 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise